| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/14/2005 | CA2545248A1 Methods for altering hematopoietic progenitor cell adhesion, differentiation, and migration |
| 04/14/2005 | CA2542004A1 Chimeric carrier molecules for the production of mucosal vaccines |
| 04/14/2005 | CA2542002A1 Methods for modulating neuronal responses using inhibitors of ampa receptor endocytosis |
| 04/14/2005 | CA2541823A1 Hypoxia responsive human cngh 0002 genes and polypeptides |
| 04/14/2005 | CA2541535A1 Antibodies to nik, their preparation and use |
| 04/14/2005 | CA2541020A1 Hypo- and hyper-acetylated meningococcal capsular saccharides |
| 04/14/2005 | CA2540896A1 Liquid vaccines for multiple meningococcal serogroups |
| 04/14/2005 | CA2540764A1 In vivo efficacy of ny-eso-1 plus adjuvant |
| 04/14/2005 | CA2540742A1 Compositions and methods for treating burns |
| 04/14/2005 | CA2540703A1 Methods and compositions for mycoplasma pneumoniae exotoxins |
| 04/14/2005 | CA2540672A1 Educated nkt cells and their uses in the treatment of immune-related disorders |
| 04/14/2005 | CA2540521A1 Anti-nik antibodies and uses thereof |
| 04/14/2005 | CA2539715A1 Pertussis antigens and use thereof in vaccination |
| 04/14/2005 | CA2539025A1 Composition for treating inflammatory bowel disease |
| 04/14/2005 | CA2537326A1 C1q related protein |
| 04/14/2005 | CA2532369A1 Immunogenic compositions for streptococcus pyogenes |
| 04/14/2005 | CA2526425A1 Antigens targeted by prevalent pathogenic t cells in type 1 diabetes and uses thereof |
| 04/14/2005 | CA2524209A1 Antiviral agents for the treatment, control and prevention of infections by coronaviruses |
| 04/14/2005 | CA2470908A1 Therapy for cancer |
| 04/13/2005 | EP1522591A2 Transgenically produced non-secreted proteins |
| 04/13/2005 | EP1522585A1 Chimeric carrier molecules for the production of mucosal vaccines |
| 04/13/2005 | EP1522579A2 Hyaluronan synthase gene and uses thereof |
| 04/13/2005 | EP1521963A2 Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby |
| 04/13/2005 | EP1521849A2 Hepatitis a virus nucleotide sequences, recombinant proteins and uses thereof |
| 04/13/2005 | EP1521832A2 Genes |
| 04/13/2005 | EP1521831A2 Transgenic animal expressing alzheimer's tau protein |
| 04/13/2005 | EP1521824A2 Nucleic acid-associated proteins |
| 04/13/2005 | EP1521822A2 Protein modification and maintenance molecules |
| 04/13/2005 | EP1521775A1 Monoclonal antibody pam4 and its use for diagnosis and therapy of pancreatic cancer |
| 04/13/2005 | EP1521774A2 Truncated tau proteins |
| 04/13/2005 | EP1521594A2 Endogenous retrovirus polypeptides linked to oncogenic transformation |
| 04/13/2005 | EP1521592A2 Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle |
| 04/13/2005 | EP1521588A2 Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors |
| 04/13/2005 | EP1521587A2 Gp41 peptides and methods based-thereon for inhibiting hiv fusion to target cells |
| 04/13/2005 | EP1521585A1 Immunostimulation by chemically modified rna |
| 04/13/2005 | EP1317484B1 Variants of the phleum pratense phl p 1 allergenic protein |
| 04/13/2005 | EP1242576B1 Stabilizing diluent for polypeptides and antigens |
| 04/13/2005 | EP0930893B1 Immunostimulatory polynucleotide/immunomodulatory molecule conjugates |
| 04/13/2005 | EP0774971B1 Synthetic peptide inhibitors of hiv transmission |
| 04/13/2005 | CN1606625A HIV-1 subtype isolate regulatory/accessory genes, and modifications and derivatives thereof |
| 04/13/2005 | CN1606624A Vaccines |
| 04/13/2005 | CN1606616A Method for the recovery and purification of poxviruses from infected cells using high pressure homogenisation |
| 04/13/2005 | CN1606569A Human antibodies that have mn binding and cell adhesion-neutralizing activity |
| 04/13/2005 | CN1606565A Nucleic acids encoding recominant 56 and 82 kda antigens from gametocytes of eimeria maxima and their uses |
| 04/13/2005 | CN1606455A Lyophilized preparation containing antibodies to the egf receptor |
| 04/13/2005 | CN1606454A Antibody targeting compounds |
| 04/13/2005 | CN1606453A Cripto blocking antibodies and uses thereof |
| 04/13/2005 | CN1605628A Human source anti-hepatitis A virus gene engineering antibody from CHO cell |
| 04/13/2005 | CN1196797C Diagnostics and therapeutics for glaucoma |
| 04/13/2005 | CN1196788C Assembly of wild-type and chimeric influenza virus-like particles (VLPS) |
| 04/13/2005 | CN1196787C Virulence genes and proteins and their use |
| 04/13/2005 | CN1196784C Promoter of human endoglin gene and its use |
| 04/13/2005 | CN1196714C Process for producing immunolobulins for intravenous administration and other immunolobulin products |
| 04/13/2005 | CN1196495C Mutant human CD80 and compositions and methods of making and using the same |
| 04/13/2005 | CN1196474C Liposome-entrapped DNA oral vaccines |
| 04/13/2005 | CN1196473C Oil adjuvant vaccine and method for preparing same |
| 04/12/2005 | US6878817 Low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis |
| 04/12/2005 | US6878816 Vmp-like sequences of pathogenic Borrelia |
| 04/12/2005 | US6878685 Purified Tat and Nef to promote localized accumulation of CD4+ cells, and an antimicrobial chemotherapeutic agent, such as an antibiotic; may also contain tumor necrosis factor-alpha |
| 04/12/2005 | US6878529 Compounds for the treatment of sexual dysfunction |
| 04/12/2005 | US6878376 Modulate immunology response |
| 04/12/2005 | US6878375 HA-1 antigen |
| 04/12/2005 | US6878372 Methods of preventing and treating flavivirus infection in animals |
| 04/12/2005 | US6878370 Chemically modified TNF-α |
| 04/12/2005 | US6877514 Organ transplantation; administering a relatively large number of stem cells, combined with the creation of thymic space without the need for whole body irradiation; mixed chimerism can be formed without hematopoietic space-creating irradiation |
| 04/12/2005 | CA2252576C Use of dipeptidyl peptidase iv inhibitors for lowering the blood glucose level in mammals |
| 04/12/2005 | CA2250704C Glial cell line-derived neurotrophic factor receptor |
| 04/12/2005 | CA2123363C Lysosomal enzyme-cleavable antitumor drug conjugates |
| 04/12/2005 | CA2113813C Immunoglobulin variants for specific fc epsilon receptors |
| 04/12/2005 | CA2108292C Process for preparing hepatitis a (hav) antigens and vaccines |
| 04/12/2005 | CA2086672C Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
| 04/12/2005 | CA2074825C Chimeric chains for receptor-associated signal transduction pathways |
| 04/07/2005 | WO2005031001A2 Novel therapeutic targets in cancer |
| 04/07/2005 | WO2005030971A1 Modified vaccinia virus ankara (mva) mutant and use thereof |
| 04/07/2005 | WO2005030964A1 Hiv pharmaccines |
| 04/07/2005 | WO2005030954A1 Process for producing antigenic substance |
| 04/07/2005 | WO2005030951A1 Royal jelly peptide and composition containing the same |
| 04/07/2005 | WO2005030931A2 Altering a b cell pathology using self-derived antigens in conjunction with specific-binding cytoreductive agent |
| 04/07/2005 | WO2005030806A2 Norovirus monoclonal antibodies and peptides |
| 04/07/2005 | WO2005030802A2 Antigens for an east coast fever vaccine |
| 04/07/2005 | WO2005030793A2 Antibodies which bind human cxcr3 |
| 04/07/2005 | WO2005030251A1 Compositions and methods to accelerate hematologic recovery |
| 04/07/2005 | WO2005030249A1 Immunotherapy method |
| 04/07/2005 | WO2005030136A2 Tumor vaccine |
| 04/07/2005 | WO2005030123A2 Botulinum antitoxin compositions and methods |
| 04/07/2005 | WO2005030122A2 Inactivated host cell delivery of polynucleotides encoding immunogens |
| 04/07/2005 | WO2005012351A8 Novel functions for decay accelerating factor (daf) in inflammation |
| 04/07/2005 | WO2005005625A3 Method for inducing hepatitis c virus (hcv) replication in vitro, cells and cell lines enabling robust hcv replication and kit therefor |
| 04/07/2005 | WO2004111608A3 Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions |
| 04/07/2005 | WO2004105791A3 Recombinant anti-lhrh vaccines |
| 04/07/2005 | WO2004096976A3 Spex compositions and methods of use |
| 04/07/2005 | WO2004094600A3 Staphylococcus aureus efb protein and c3 binding region which inhibit complement activation |
| 04/07/2005 | WO2004092207A3 Respiratory syncytial virus (rsv) peptides |
| 04/07/2005 | WO2004066957A3 ANTI-INTEGRIN ανβ3 ANTIBODY FORMULATIONS AND USES THEREOF |
| 04/07/2005 | WO2004032857A8 Antibody therapy |
| 04/07/2005 | WO2004029092A8 Antibody for adcc and inducing cytokine production |
| 04/07/2005 | WO2004013309A3 PAPSSs AS MODIFIERS OF THE AXIN PATHWAY AND METHODS OF USE |
| 04/07/2005 | WO2004006847A3 Selected antibodies and duramycin peptides binding to anionic phospholipids and aminophospholipids and their use in treating viral infections and cancer |
| 04/07/2005 | WO2004001072A3 Method for diagnosis of colorectal tumors |
| 04/07/2005 | WO2003093416A3 Protective antigens for the control of ixodes species infestations |